GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 16,061,751 shares, an increase of 29.7% from the March 15th total of 12,381,329 shares. Approximately 0.9% of the company's shares are sold short. Based on an average daily trading volume, of 4,478,287 shares, the days-to-cover ratio is presently 3.6 days.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of GSK in a research note on Friday, January 16th. Weiss Ratings lowered shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, March 19th. TD Cowen reaffirmed a "hold" rating on shares of GSK in a research note on Monday, February 9th. Wall Street Zen lowered shares of GSK from a "strong-buy" rating to a "buy" rating in a research note on Saturday, March 7th. Finally, Morgan Stanley reaffirmed an "underweight" rating on shares of GSK in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, GSK currently has an average rating of "Reduce" and a consensus price target of $53.00.

GSK Stock Down 2.2%

Shares of GSK opened at $57.86 on Thursday. The stock has a market capitalization of $117.54 billion, a PE ratio of 15.64, a P/E/G ratio of 3.45 and a beta of 0.46. GSK has a 1 year low of $35.08 and a 1 year high of $61.69. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.54 and a current ratio of 0.82. The company's 50-day simple moving average is $56.74 and its 200-day simple moving average is $50.77.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 9th. Shareholders of record on Friday, February 20th were given a $0.4856 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $1.94 dividend on an annualized basis and a dividend yield of 3.4%. This is a boost from GSK's previous quarterly dividend of $0.42. GSK's payout ratio is currently 50.81%.

Institutional Investors Weigh In On GSK

A number of large investors have recently modified their holdings of the company. Fisher Asset Management LLC increased its position in shares of GSK by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company's stock valued at $1,627,931,000 after purchasing an additional 968,370 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its position in shares of GSK by 2,032.8% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company's stock valued at $41,896,000 after purchasing an additional 814,275 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of GSK by 1.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company's stock valued at $15,444,000 after purchasing an additional 4,855 shares during the last quarter. Ethic Inc. increased its position in shares of GSK by 9.1% in the 3rd quarter. Ethic Inc. now owns 174,093 shares of the pharmaceutical company's stock valued at $7,514,000 after purchasing an additional 14,505 shares during the last quarter. Finally, Bard Financial Services Inc. increased its position in shares of GSK by 17.4% in the 3rd quarter. Bard Financial Services Inc. now owns 158,145 shares of the pharmaceutical company's stock valued at $6,826,000 after purchasing an additional 23,400 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK's core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.